Literature DB >> 27403293

The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia.

Krystien Vv Lieve1, Arthur A Wilde2, Christian van der Werf1.   

Abstract

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare but severe genetic cardiac arrhythmia disorder, with symptoms including syncope and sudden cardiac death due to polymorphic VT or ventricular fibrillation typically triggered by exercise or emotions in the absence of structural heart disease. The cornerstone of medical therapy for CPVT is β-blockers. However, recently flecainide has been added to the therapeutic arsenal for CPVT. In this review we summarise current data on the efficacy and role of flecainide in the treatment of CPVT.

Entities:  

Keywords:  Antiarrhythmic therapy; catecholaminergic ventricular tachycardia; flecainide; genetic; inherited channelopathies; sudden death

Year:  2016        PMID： 27403293      PMCID： PMC4939313          DOI： 10.15420/aer.2016.3.3

Source DB:  PubMed          Journal:  Arrhythm Electrophysiol Rev        ISSN： 2050-3369


  40 in total

1.  Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of β-blockade.

Authors:  Gareth J Padfield; Leenah AlAhmari; Krystien V V Lieve; Tasneem AlAhmari; Thomas M Roston; Arthur A Wilde; Andrew D Krahn; Shubhayan Sanatani
Journal:  Heart Rhythm       Date:  2015-09-28       Impact factor: 6.343

2.  Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.

Authors:  Christian van der Werf; Prince J Kannankeril; Frederic Sacher; Andrew D Krahn; Sami Viskin; Antoine Leenhardt; Wataru Shimizu; Naokata Sumitomo; Frank A Fish; Zahurul A Bhuiyan; Albert R Willems; Maurits J van der Veen; Hiroshi Watanabe; Julien Laborderie; Michel Haïssaguerre; Björn C Knollmann; Arthur A M Wilde
Journal:  J Am Coll Cardiol       Date:  2011-05-31       Impact factor: 24.094

3.  Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity.

Authors:  Nian Liu; Marco Denegri; Yanfei Ruan; José Everardo Avelino-Cruz; Andrea Perissi; Sara Negri; Carlo Napolitano; William A Coetzee; Penelope A Boyden; Silvia G Priori
Journal:  Circ Res       Date:  2011-06-16       Impact factor: 17.367

4.  Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia.

Authors:  Raymond W Sy; Michael H Gollob; George J Klein; Raymond Yee; Allan C Skanes; Lorne J Gula; Peter Leong-Sit; Robert M Gow; Martin S Green; David H Birnie; Andrew D Krahn
Journal:  Heart Rhythm       Date:  2011-02-09       Impact factor: 6.343

5.  A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel.

Authors:  H Lahat; E Pras; T Olender; N Avidan; E Ben-Asher; O Man; E Levy-Nissenbaum; A Khoury; A Lorber; B Goldman; D Lancet; M Eldar
Journal:  Am J Hum Genet       Date:  2001-10-25       Impact factor: 11.025

6.  Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation.

Authors:  Gaetano M De Ferrari; Veronica Dusi; Carla Spazzolini; J Martijn Bos; Dominic J Abrams; Charles I Berul; Lia Crotti; Andrew M Davis; Michael Eldar; Maria Kharlap; Asaad Khoury; Andrew D Krahn; Antoine Leenhardt; Christopher R Moir; Attilio Odero; Louise Olde Nordkamp; Thomas Paul; Ferran Rosés I Noguer; Maria Shkolnikova; Jan Till; Arthur A M Wilde; Michael J Ackerman; Peter J Schwartz
Journal:  Circulation       Date:  2015-05-27       Impact factor: 29.690

7.  Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.

Authors:  Hiroshi Watanabe; Christian van der Werf; Ferran Roses-Noguer; Arnon Adler; Naokata Sumitomo; Christian Veltmann; Raphael Rosso; Zahurul A Bhuiyan; Hennie Bikker; Prince J Kannankeril; Minoru Horie; Tohru Minamino; Sami Viskin; Björn C Knollmann; Jan Till; Arthur A M Wilde
Journal:  Heart Rhythm       Date:  2012-12-31       Impact factor: 6.343

8.  A de novo novel cardiac ryanodine mutation (Ser4155Tyr) associated with catecholaminergic polymorphic ventricular tachycardia.

Authors:  Lilian Mantziari; Vassilios Vassilikos; Aris Anastasakis; Xanthippi Kotsaka; Stelios Paraskevaidis; Ioannis H Styliadis; David Luria
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-10-23       Impact factor: 1.468

9.  Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans.

Authors:  Hiroshi Watanabe; Nagesh Chopra; Derek Laver; Hyun Seok Hwang; Sean S Davies; Daniel E Roach; Henry J Duff; Dan M Roden; Arthur A M Wilde; Björn C Knollmann
Journal:  Nat Med       Date:  2009-03-29       Impact factor: 53.440

Review 10.  Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation.

Authors:  Etienne Aliot; Alessandro Capucci; Harry J Crijns; Andreas Goette; Juan Tamargo
Journal:  Europace       Date:  2010-12-07       Impact factor: 5.214
View more
  8 in total

1.  Advancements in the use of gene therapy for cardiac arrhythmia.

Authors:  Nathaniel P Murphy; Ellen R Lubbers; Peter J Mohler
Journal:  Heart Rhythm       Date:  2017-04-04       Impact factor: 6.343

Review 2.  Modeling Inherited Arrhythmia Disorders Using Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Authors:  Vassilios J Bezzerides; Donghui Zhang; William T Pu
Journal:  Circ J       Date:  2016-12-03       Impact factor: 2.993

3.  For Whom the Bell Tolls : Refining Risk Assessment for Sudden Cardiac Death.

Authors:  Ivaylo Tonchev; David Luria; David Orenstein; Chaim Lotan; Yitschak Biton
Journal:  Curr Cardiol Rep       Date:  2019-08-02       Impact factor: 2.931

Review 4.  Multiple targets for flecainide action: implications for cardiac arrhythmogenesis.

Authors:  Samantha C Salvage; Karthik H Chandrasekharan; Kamalan Jeevaratnam; Angela F Dulhunty; Andrew J Thompson; Antony P Jackson; Christopher L-H Huang
Journal:  Br J Pharmacol       Date:  2017-05-12       Impact factor: 8.739

Review 5.  Ion Channel Disorders and Sudden Cardiac Death.

Authors:  Anna Garcia-Elias; Begoña Benito
Journal:  Int J Mol Sci       Date:  2018-02-28       Impact factor: 5.923

6.  Magnetocardiographic evaluation of nonarrhythmogenic flecainide-induced electrocardiographic T-wave inversion.

Authors:  Donatella Brisinda; Anna Rita Sorbo; Lara La Brocca; Riccardo Fenici
Journal:  Anatol J Cardiol       Date:  2017-04       Impact factor: 1.596

7.  Safety and efficacy of flecainide for patients with catecholaminergic polymorphic ventricular tachycardia: A systematic review and meta-analysis.

Authors:  Guangqiang Wang; Na Zhao; Shu Zhong; Yingrong Wang; Jianping Li
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

8.  Deciphering DSC2 arrhythmogenic cardiomyopathy electrical instability: From ion channels to ECG and tailored drug therapy.

Authors:  Adrien Moreau; Jean-Baptiste Reisqs; Helene Delanoe-Ayari; Marion Pierre; Alexandre Janin; Antoine Deliniere; Francis Bessière; Albano C Meli; Azzouz Charrabi; Estele Lafont; Camille Valla; Delphine Bauer; Elodie Morel; Vincent Gache; Gilles Millat; Xavier Nissan; Adele Faucherre; Chris Jopling; Sylvain Richard; Alexandre Mejat; Philippe Chevalier
Journal:  Clin Transl Med       Date:  2021-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.